Endocrine Abstracts

Introduction: GH deficiency (GHD) leads to altered body composition, lipid metabolism and quality of life, and is also associated to an increased cardiovascular morbidity and mortality. The aim of this study was to evaluate long-term changes after treatment with GH replacement therapy (GHRT).Methods: We retrospectively reviewed adult patients with GHD in our clinic who were treated with GHRT. We evaluated demographic (etiology, age, dose), anthropometric...

IntroductionFasting trial remains the gold standard to confirm the diagnosis of insulinoma, based on low blood glucose level concomitant with inadequate high insulin level. However, diagnostic criteria are not consensual. Glycemia and insulin thresholds differ between the different consensus statements : endogenous hyperinsulism diagnosis relies on a glycemia < 3 mmol/l associated with an insulin level > 3 mUI/l in Endocrine Society guidelines (2009)...

IntroductionResponse to Therapy, according to ATA’s dynamic classification, provides a description of the clinical situation in patients with thyroid cancer (TC) a year or more after treatment. It gives us more accurate information than the obtained at diagnosis by static staging systems as AJCC and ATA risk system.ObjetivesTo analyse the association between some factors collected at diagnosis and the ty...

Thyroid cancer is the most common type of endocrine tumor and reaches the peak of incidence between the age of twenty and fifty years. It has 4-fold higher prevalence in females than males, suggesting that estrogens and their receptors could be involved in thyroid cancer pathogenesis. Previous studies demonstrated allosteric interference operated by G protein-coupled estrogen receptor (GPER) to molecules structurally similar to the thyroid-stimulating hormone (TSH) receptor (T...

Objectives: Anaplastic thyroid cancer (ATC) is one of the deadliest cancers, with a median overall survival (OS) of 4 months and a disease-specific mortality of ˜100%. Although to date no effective treatment can cure the disease, some anecdotal cases achieved longer survival and very rarely the cure of the disease. Multimodal treatment with surgery, radiotherapy, multikinase inhibitors (MKI) could improve survival in ATC, particularly when surgery is not feasible.<p c...

Sporadic medullary thyroid cancer (sMTC) presents mutations of the RET proto-oncogene in about 50% of the cases and of the RAS proto-oncogene in about 20% of the cases. In about 15% of cases, sMTC is multifocal and it is not known whether multiple foci can be considered as intrathyroidal metastases of the main tumor focus or if they can be considered as independent tumors. To clarify this issue, we examined the mutation profile of multiple intrathyroidal tumo...

Background: Follicle-stimulating hormone receptor (FSHR) and G protein-coupled estrogen receptor (GPER) are expressed on the surface of granulosa cells, where they form heteromeric complexes, shifting FSH-induced signals to survival pathways and determining the follicular fate.Objectives: We evaluated whether GPER can interact with the luteinizing hormone (LH)/choriogonadotropin (hCG) receptor (LHCGR) and modulate the LH/hCG/dependent signalling pathways...

Background: GI neuroendocrine tumors express somatostatin (SSTR) receptors, and the radioloabeled SSTR analog Lu-177-DOTATATE is an FDA-approved systemic treatment for those with metastatic disease. Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) which inhibits cells from repairing damaged DNA, especially single-stranded DNA breaks caused by beta particle emissions from the radioactive decay of Lu-177. We report the first results of a phase 1/2 study evaluating th...

Background: Metastatic GI Neuroendocrine Tumors (GI-NET) and pheochromocytoma/paraganglioma (PPGL) are are tumors which overexpresses somatostatin receptors (SSTR) and can be treated with targeted radioligand therapy (RLT) such as Lu-177-DOTATATE. However, despite demonstrated clinical efficacy at stabilizing tumor growth, durable response is very rare and almost all patients inevitably progresses at some time after treatment. Good systemic therapy options after beta-emiting R...

Introduction: In the past few years, advances in technology applied to diabetes have significantly changed the type 1 diabetes management. However, only a minority of patients with type 1 diabetes achieves the recommended glycemic goals. Advanced Hybrid Closed-Loop (AHCL) systems, which combine continuous glucose monitoring (CGM) with a continuous subcutaneous insulin infusion (CSII) pump and a control algorithm, improve glycemic control and patient-reported outcomes, such as ...